Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors

被引：27
|
作者：
Cox, Jason M.
Harper, Bart
Mastracchio, Anthony
Leiting, Barbara
Roy, Ranabir Sinha
Patel, Reshma A.
Wu, Joseph K.
Lyons, Kathryn A.
He, Huaibing
Xu, Shiyao
Zhu, Bing
Thornberry, Nancy A.
Weber, Ann E.
Edmondson, Scott D.
机构：
[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA
[3] Merck & Co Inc, Dept Drug Metab, Rahway, NJ 07065 USA
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 16期
关键词：
dipeptidyl peptidase IV; DPP-4; DPP8; DPP9; QPP; aminopiperidine;
D O I：
10.1016/j.bmcl.2007.05.087
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Substituted 3-aminopiperidines 3 were evaluated as DPP-4 inhibitors. The inhibitors showed good DPP-4 potency with Superb selectivity over other peptidases (QPP, DPP8, and DPP9). Selected DPP-4 inhibitors were further evaluated for their hERG potassium channel, calcium channel, Cyp2D6, and pharmacokinetic profiles. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4579 / 4583
页数：5
相关论文
共 50 条
  • [31] Potent inhibitors of dipeptidyl peptidase IV and their mechanisms of inhibition
    Stöckel-Maschek, A
    Stiebitz, B
    Born, I
    Faust, J
    Mögelin, W
    Neubert, K
    CELLULAR PEPTIDASES IN IMMUNE FUNCTIONS AND DISEASES 2, 2000, 477 : 117 - 123
  • [32] Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors
    Zhao, GH
    Taunk, PC
    Magnin, DR
    Simpkins, LM
    Robl, JA
    Wang, AY
    Robertson, JG
    Marcinkeviciene, J
    Sitkoff, DF
    Parker, RA
    Kirby, MS
    Hamann, LG
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (18) : 3992 - 3995
  • [33] Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors
    Barlaam, Bernard
    Cadogan, Elaine
    Campbell, Andrew
    Colclough, Nicola
    Dishington, Allan
    Durant, Stephen
    Goldberg, Kristin
    Hassall, Lorraine A.
    Hughes, Gareth D.
    MacFaul, Philip A.
    McGuire, Thomas M.
    Pass, Martin
    Patel, Anil
    Pearson, Stuart
    Petersen, Jens
    Pike, Kurt G.
    Robb, Graeme
    Stratton, Natalie
    Xin, Guohong
    Zhai, Baochang
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (08): : 809 - 814
  • [34] Discovery of Novel Pyrazolopyrimidines as Potent, Selective, and Orally Bioavailable Inhibitors of ALK2
    Nguyen, Minh H.
    Atasoylu, Onur
    Wu, Liangxing
    Kapilashrami, Kanishk
    Pusey, Michelle
    Gallagher, Karen
    Lai, Cheng-Tsung
    Zhao, Peng
    Barbosa, Joseph
    Liu, Kai
    He, Chunhong
    Zhang, Colin
    Styduhar, Evan D.
    Witten, Michael R.
    Chen, Yaoyu
    Lin, Luping
    Yang, Yan-ou
    Covington, Maryanne
    Diamond, Sharon
    Yeleswaram, Swamy
    Yao, Wenqing
    ACS MEDICINAL CHEMISTRY LETTERS, 2022, : 1159 - 1164
  • [35] Discovery of potent, selective, orally bioavailable Stearoyl-CoA desaturase 1 inhibitors
    Liu, Gang
    Lynch, John K.
    Freeman, Jennifer
    Liu, Bo
    Xin, Zhili
    Zhao, Hongyu
    Serby, Michael D.
    Kym, Philip R.
    Suhar, Tom S.
    Smith, Harriet T.
    Cao, Ning
    Yang, Ruojing
    Janis, Rich S.
    Krauser, Joel A.
    Cepa, Steven P.
    Beno, David W. A.
    Sham, Hing L.
    Collins, Christine A.
    Surowy, Teresa K.
    Camp, Heidi S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (13) : 3086 - 3100
  • [36] Discovery and optimization of orally bioavailable, selective and potent ATP-independent Akt inhibitors
    Chan, Thomas C. K.
    Ashwell, Mark A.
    Lapierre, Jean-Marc
    Brassard, Christopher
    Bull, Cathy
    Cornell-Kennon, Susan
    Eathiraj, Sudharshan
    France, Dennis S.
    Hill, Jason
    Koerner, Steffi
    Kelleher, Eoin
    Kizer, Darin
    Liu, Yanbin
    Link, Jeff
    Makhija, Sapna
    Moussa, Magdi
    Namdev, Nivedita
    Nicewonger, Robert
    Uppalapati, Uma
    Palma, Rocio
    Szwaya, Jeff
    Tandon, Manish
    Vensel, David
    Volak, Laurie
    Volckova, Erika
    Westland, Neil
    Wu, Hui
    Yang, Rui-Yang
    CANCER RESEARCH, 2012, 72
  • [37] Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors
    Ferraris, D
    Ko, YS
    Calvin, D
    Chiou, T
    Lautar, S
    Thomas, B
    Wozniak, K
    Rojas, C
    Kalish, V
    Belyakov, S
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (22) : 5579 - 5583
  • [38] Development of potent and selective dipeptidyl peptidase II inhibitors
    Senten, K
    Van der Veken, P
    Bal, G
    De Meester, I
    Lambeir, AM
    Scharpé, S
    Bauvois, B
    Haemers, A
    Augustyns, K
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (20) : 2825 - 2828
  • [39] Discovery of potent and orally bioavailable 17β-hydroxysteroid dehydrogenase type 3 inhibitors
    Harada, Koichiro
    Kubo, Hideki
    Abe, Jun
    Haneta, Mari
    Conception, Arnel
    Inoue, Shinichi
    Okada, Satoshi
    Nishioka, Kazuhiko
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (10) : 3242 - 3254
  • [40] LC15-0444 is a novel, potent, selective, and orally active dipeptidyl peptidase IV inhibitor
    Hwang, Dal-Ml
    Kim, Sung-Ho
    Yoon, Min-Kyung
    Kwon, O. Hwan
    Goo, Kidong
    Min, Changhee
    Lee, Sung-Hack
    Lee, Jaeick
    Lee, Chang-Seok
    Yim, Hyeon Joo
    DIABETES, 2008, 57 : A150 - A150
12345